Pharmidex
Martin Barrett has extensive experience in the pharmaceutical industry, currently serving as the Head of Business Development at Pharmidex since January 2013, after previously holding the position of Business Development Manager. Prior to Pharmidex, Martin worked at Vertex Pharmaceuticals for over a decade, advancing to the role of Senior Research Scientist. Additional experience includes a position as Section Manager at Aventis and as a Senior Scientist at Rhone-Poulenc Rorer. Martin holds a Ph.D. in Pharmaceutics from King's College London and a degree in Biological Sciences with a focus on Physiology and Microbiology from the University of Plymouth.
This person is not in any teams
This person is not in any offices
Pharmidex
Pharmidex is an AAALAC-accredited, UK-based CRO founded in 2002. We provide high-quality, cost-effective, flexible and rapid solutions in drug metabolism and pharmacokinetics (DMPK), bioanalysis (non-GLP/GLP/GCP), toxicology (non-GLP/GLP), histology, clinical chemistry, hematology, and in vitro ADME. Pharmidex also offers in silico modelling and efficacy models supporting oncology, CNS, respiratory, stroke, autoimmune, and metabolic disease programs. We work with over 250 global clients, including medical charities, academic groups, biotech, and pharma, and have undertaken over 15,000 studies. In addition to our fee-for-service offering, Pharmidex actively seeks collaboration opportunities in grant-funded projects. To date, we have successfully participated in over 30 collaborative grant-funded projects, partnering with more than 167 global collaborators.